Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis.
Neonatal sepsis is a major cause of death and disability in newborns. Commonly used biomarkers for diagnosis and evaluation of treatment response lack sufficient sensitivity or specificity. Additionally, new targets to treat the dysregulated immune response are needed, as are methods to effectively screen drugs for these targets. Available research methods have hitherto not yielded the breakthroughs required to significantly improve disease outcomes, we therefore describe the potential of zebrafish (Danio rerio) larvae as preclinical model for neonatal sepsis. In biomedical research, zebrafish larvae combine the complexity of a whole organism with the convenience and high-throughput potential of in vitro methods. This paper illustrates that zebrafish exhibit an immune system that is remarkably similar to humans, both in terms of types of immune cells and signaling pathways. Moreover, the developmental state of the larval immune system is highly similar to human neonates. We provide examples of zebrafish larvae being used to study infections with pathogens commonly causing neonatal sepsis and discuss known limitations. We believe this species could expedite research into immune regulation during neonatal sepsis and may hold keys for the discovery of new biomarkers and novel treatment targets as well as for screening of targeted drug therapies.
['Keij|Fleur M|FM|https://orcid.org/0000-0002-1469-1952', 'Koch|Bjørn E V|BEV|', 'Lozano Vigario|Fernando|F|', 'Simons|Sinno H P|SHP|', 'van Hasselt|Johan G C|JGC|', 'Taal|H Rob|HR|', 'Knibbe|C A J|CAJ|', 'Spaink|Herman P|HP|', 'Reiss|Irwin K M|IKM|', 'Krekels|Elke H J|EHJ|']
zebrafish larvae Neonatal sepsis biomarker discovery drug development preclinical disease model